Totiger, Tulasigeri M.

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Montoya, S., Bourcier, J., Noviski, M., Lu, H., Thompson, M. C., Chirino, A., Jahn, J., Sondhi, A. K., Gajewski, S., Tan, Y. S. (., et al. (2024) · Science

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 175

E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

Bewersdorf, J. P., Stahl, M., Taylor, J., Mi, X., Chandhok, N. S., Watts, J., Derkach, A., Wysocki, M., Lu, S. X., Bourcier, J., et al. (2023) · Leukemia

Acute Myeloid Leukemia ResearchRNA Research and Splicing

Cited by 62

XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Kruer, T. L., Quintana, A., Ferrall-Fairbanks, M., Zhang, L., Newman, H., McLemore, A. F., Yang, Q., Bencrentsil, N., Komrokji, R. S., Chaudhry, S., et al. (2022) · Blood

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 8